Home > Cardiology > Rivaroxaban not inferior to warfarin for afib patients with artificial mitral valve

Rivaroxaban not inferior to warfarin for afib patients with artificial mitral valve

Journal
New England Journal of Medicine
Conference
AHA 2020
Reuters Health - 16/11/2020 - A comparison of rivaroxaban and warfarin in patients with atrial fibrillation and a bioprosthetic mitral valve has concluded that rivaroxaban is not inferior when it comes to a combination outcome of death, major bleeding and major cardiovascular events at 12 months. And while it wasn't superior either, it did significantly reduce the risk of stroke. The randomized trial, known as RIVER, involved 1,005 patients, making it the largest to evaluate the safety and efficacy of direct oral anticoagulation for valve recipients who also had atrial fibrillation or flutter. A primary-endpoint event typically occurred at the 347.5-day mark among the rivaroxaban group versus at 340.5 days among patients getting warfarin. Those seven extra days free of primary-endpoint events cost about $5,600, according to prices for the two drugs available at goodrx.com. "I believe it is not a very high price in order to gain time free from ma...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on